Adicet Bio, Inc.

Stage 4 · Declining · week 1

As of Oct 22, 2026, Adicet Bio is in Stage 4, the downtrend phase, now in its first week (since Oct 21, 2026). It closed at $4.28, 70.7% below its 52-week high and below its 200-day average, which is falling.

$4.28

-4.89% today

$40.1M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ACET early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 19w

S4 14w

S4 34w

S4 20w

S1 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 19w → S1 9w → S2 5w → S3 7w → S4 14w → S1 8w → S4 34w → S1 8w → S4 3w → S1 4w → S2 5w → S3 4w → S4 20w → S1 14w → S2 8w → S3 2w → S4 1w current

Total tracked: 165 weeks across 17 stage runs.

ACET among Biotechnology429th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…429	ACETAdicet Bio, Inc.	Stage 4 · wk 1	15	−49.6%

vs 52W High

-70.7%

$4.28 lo$14.59 hi

70.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-45.3%

200 DMA: $7.82 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.73x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-49.6%

-45.1%

-45.8%

YTD

-51.5%

-71.0%

Scan Membership

Breakout Watch

Latest: 2024-02-29

9 appearances in last 60 days. First seen: 2018-11-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 1 · Vol 0.73x

2026-10-21S43→4

Wk 1 · Vol 0.80x

2026-10-20S3

Wk 3 · Vol 0.60x

2026-10-19S3

Wk 3 · Vol 1.10x

2026-10-16S3

Wk 2 · Vol 0.90x

2026-10-15S3

Wk 2 · Vol 0.75x

2026-10-14S3

Wk 2 · Vol 1.77x

2026-10-13S3

Wk 2 · Vol 1.65x

2026-10-12S3

Wk 2 · Vol 0.74x

2026-10-09S3

Wk 1 · Vol 0.97x

2026-10-08S3

Wk 1 · Vol 2.61x

2026-10-07S3

Wk 1 · Vol 1.17x

Moving averages & range

50 DMA

$7.76

200 DMA

$7.82

52W High

$14.59

52W Low

$4.28

5D Low

$4.28

Resistance levels (recent highs)

20d High

$9.02

60d High

$9.73

120d High

$9.73

250d High

$14.43

Next resistance

+110.7%

to 20d High

ROE

-78.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.4

Adicet Bio: quick answers

What stage is Adicet Bio in?

As of Oct 22, 2026, Adicet Bio (ACET) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is Adicet Bio in an uptrend?

No. Adicet Bio is in a Stage 4 downtrend. It trades 45.3% below its 200-day average, which is falling.

How far is Adicet Bio from its 52-week high?

Adicet Bio closed at $4.28 on Oct 22, 2026, 70.7% below its 52-week high of $14.59. Its 52-week low is $4.28.

How has Adicet Bio performed over the past year?

As of Oct 22, 2026, Adicet Bio is down 71.0% over the past year and down 51.5% so far in 2026.

Which sector and industry is Adicet Bio in?

Adicet Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.